While early data is promising and many anticipate that retatrutide may soon be available by prescription through legitimate medical channels, it is still in phase 3 clinical trials and has not been approved by the FDA for prescription use or sale
However, it is generally less potent for weight loss due to reduced absorption and strict daily dosing requirements, which can make consistency more difficult
A case report documented clinical remission in a 42-year-old UC patient following liraglutide administration for obesity treatment (96)
Mounjaro has a structured dose ladder
Researchers also associate ending GLP-1 therapy before pregnancy with a few risks.* Women who stopped taking a GLP-1 RA before or during early pregnancy had roughly 1.3x the risk of preterm birth, gestational diabetes, and high blood pressure conditions during pregnancy, compared to similar women who had not taken a GLP-1 RA
"Impact of drug transporter studies on drug discovery and development"